Press Releases AstraZeneca PLC Nasdaq Stockholm

Equities

AZN

GB0009895292

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
1,676 ^SEK	+2.38%		+3.65%	+23.83%

Jul. 12	Instil Bio Shares Surge Following Rental Agreement with AstraZeneca	DJ
Jul. 12	Sector Update: Health Care Stocks Mixed Premarket Friday	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Selkirk Pharma, Inc. - Colleen Dixon Appointed CEO	Jul. 10	AQ
Non-Hodgkin Lymphoma Pipeline 2024 \| Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences	Jul. 09	AQ
Metastatic Renal Cell Carcinoma Pipeline 2024 \| AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics	Jul. 09	AQ
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series a Cumulative Redeemable Perpetual Preferred Stock	Jul. 08	AQ
Astrazeneca - Tagrisso with the addition of chemotherapy approved in the EU as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer	Jul. 08	AQ
BenevolentAI - Leadership team change	Jul. 04	AQ
Astrazeneca - Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advanced or recurrent endometrial cancer	Jul. 02	AQ
Astrazeneca - Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention	Jul. 02	AQ
AstraZeneca : Transparency Directive Form 6 K	Jul. 01	PU
AstraZeneca : Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advanced or recurrent endometrial cancer Form 6 K	Jul. 01	PU
Astrazeneca - Tagrisso with the addition of chemotherapy approved in China as 1st-line treatment for patients with EGFR-mutated advanced lung cancer	Jun. 27	AQ
Astrazeneca - IMFINZI demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial	Jun. 26	AQ
Astrazeneca - Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer	Jun. 26	AQ
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial	Jun. 25	BU
AstraZeneca : Update on Imfinzi ADJUVANT BR.31 trial	Jun. 25	PU
AstraZeneca : Imfinzi improved EFS and OS in bladder cancer	Jun. 25	PU
Astrazeneca - Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy in advanced or metastatic triple-negative breast cancer	Jun. 19	AQ
Squamous Cell Carcinoma Pipeline 2024 \| FDA Approvals, Clinical Trials, Therapies, MOA, ROA \| Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna	Jun. 19	AQ
AstraZeneca - IMFINZI plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer	Jun. 18	AQ
AstraZeneca : Update on CAPItello-290 Phase III trial	Jun. 18	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT